Scientists have engineered probiotic bacteria to act as tiny drug factories inside pancreatic tumors, offering a promising new approach to cancer treatment. In animal studies, the modified bacteria were able to enter pancreatic tumors and stimulate cancer-fighting immune cells, helping slow tumor growth. The treatment became even more effective when combined with conventional therapies such as chemotherapy, radiation, or immunotherapy. By delivering therapeutic activity directly within the tumor environment, engineered probiotics could potentially overcome some of the challenges of treating pancreatic cancer, which is often difficult to target and highly resistant to treatment. However, the approach remains experimental, and further studies are needed to determine its safety, effectiveness, and potential for use in human patients.
Read more at ScienceDaily